Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Non-Deal Roadshow (July 2021)
20 slides from Proteomics International Laboratories's roadshow presentation, Jul 20, 2021
Slide 1: ASX Release: Investor Presentation
ASX Release 20 July 2021 ASX code: PIQ Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to release a copy of its latest investor presentation for a non-deal roadshow to existing and potential new institutional investors. Authorised by th
Slide 2: Proteomics International Investor Presentation
ASX: PIQ Proteomics International LABORATORIES LTD Investor Presentation July 2021 Non-deal Roadshow Dr. Richard Lipscombe Managing Director
Slide 3: Disclaimer
Disclaimer ASX: PIQ ASX:PIQ This Presentation is provided by Proteomics International Laboratories Ltd (ASX: PIQ, Proteomics International, Proteomics, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associ
Slide 4: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ ASX:PIQ A medical technology company at the forefront of Corporate Snapshot – 16/07/2021 precision medicine and predictive diagnostics ASX code PIQ Share Price A$1.08 Diagnostics Shares on issue (+8.0m options) 105m PromarkerD Market Capitalisation
Slide 5: Board of Directors
Board of Directors ASX: PIQ ASX:PIQ South & Terry Sweet FAICD, Chairman Central America Director of several listed companies over the past 30 years in both executive and non-executive capacities. Companies include XRF Scientific Ltd, where he was Managing Director for 4 years, Western Biotechnology
Slide 6: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ ASX:PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 5
Slide 7: Changing Lives: A new blood test for predicting diabetic kidney disease
PromarkerD CHANGING LIVES Anew blood test for predicting diabetic kidney disease
Slide 8: Problem & Solution
Problem & Solution ASX: PIQ ASX:PIQ Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the Roadblock onset of diabetic kidney disease The Problem • Patients ul
Slide 9: PromarkerD is Revenue Ready
PromarkerD is Revenue Ready ASX: PIQ The PromarkerD predictive test is poised to roll-out in markets globally ASX:PIQ Enormous Market ✓ 463m adults have diabetes globally - 1 in 3 currently have DKD High Statistical Performance ✓ Peer reviewed publications – Clinical & analytical validity proven (Se
Slide 10: PromarkerD – Simple Integration & Utilisation
PromarkerD – Simple Integration & Utilisation ASX: PIQ ASX:PIQ Blood Sample drawn Biomarkers Analysed Results analysed by Results and intervention PromarkerD Hub software plan delivered Sample is drawn at clinic Laboratory uses a standard Cloud based algorithm, the Clinician delivers results or path
Slide 11: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention How PromarkerDTM results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabetes management Test Annually •
Slide 12: PromarkerD in the Clinic
PromarkerD in the Clinic ASX: PIQ PromarkerD significantly enhances diabetic kidney disease diagnosis and management ASX:PIQ Peer reviewed PromarkerD tested on over 5,000 patients in 4-year clinical studies PromarkerD predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney
Slide 13: PromarkerD Market Opportunity
PromarkerD Market Opportunity ASX: PIQ ASX:PIQ Diabetes incidence and Patent portfolio 50% undiagnosed Country Patent/Application No Patent Status No. Diabetics1 Australia 2011305050 Granted 1,288,300 Brazil BR112013006740 Granting 16,780,800 Canada 2811654 Granted 2,793,500 China ZL201180053583.9 G
Slide 14: PromarkerD – Route To Market
PromarkerD – Route To Market ASX: PIQ ASX:PIQ Diagnostic company / laboratory Laboratory conducts tests & submits raw Laboratory pays PIQ a royalty per license PromarkerDTM data to PromarkerD hub test Immunoassay kits PromarkerD Hub calculates ‘risk score’ manufactured and supplied and sends report
Slide 15: Diagnostics Pipeline
Diagnostics Pipeline ASX: PIQ ASX:PIQ Further Global Potential in New Markets ▪ Employs the Promarker™️ technology platform to develop novel intellectual property The Promarker™️ Research ▪ Targeting new diagnostic tests in areas of significant unmet need Pipeline & Timeline ▪ Enormous markets and r
Slide 16: In Development: Endometriosis
In Development: Endometriosis What is Endometriosis? • A debilitating condition in which tissue that normally lines the uterus grows outside the uterus (on the ovaries, fallopian tubes or the intestines) • The most common symptoms are chronic pain and menstrual irregularities • Diagnosis typically t
Slide 17: Promarker Timeline & Upcoming Milestones
Promarker™️ Timeline & Upcoming Milestones ASX: PIQ Two-year targets and achievements (2019 & 2020) 2021 targets ASX:PIQ November 2018 Additional June 2020 Proteomics enters Licensing deals for Big pharma PromarkerD November 2019 PromarkerD with (Janssen) clinical collaboration with US diagnostic, C
Slide 18: 2021/22 Value Inflection Points
2021/22 Value Inflection Points ASX: PIQ ASX:PIQ Exceptional Global Share Price Catalysts 2021/22 Opportunity Milestone 2021 Sep'Q Dec'Q Mar'Q CY’22 Impact ➢ Cutting-edge technology & proven in-house diagnostics platform PromarkerD Licensing Deals US & EU Drive global uptake and future revenue ➢ Pro
Slide 19: Peer Comparison
Peer Comparison ASX: PIQ ASX:PIQ Market Share 1HF Y21 1HF Y21 Net Stock Code Company Focus Capitalisation Price Revenue Profit/Loss DKD test based on AI and a combination of predictive blood-based biomarkers, genetic RENX.LSE 970p & factors and electronic health records. ~A$1.52Bn N/A US$9.3m loss R
Slide 20: Contact
Contact ASX: PIQ ASX:PIQ Dr Richard Lipscombe Dirk van Dissel Managing Director Corporate Advisor & Investor Relations T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au Kyle Moss Corporate Ad
Proteomics International Laboratories — Non-Deal Roadshow (July 2021) on 6ix